

Fig. 2 Association of *FTO*-rs9939609 (or proxy) with obesity. Study-specific association analyses assumed an additive genetic model, comparing obese with normal-weight individuals, adjusted for age and

sex. Effect sizes were combined using random-effects meta-analyses (DerSimonian–Laird method)

mainly due to difference in mean age and mean BMI among different populations. For hip circumference, the heterogeneity was mainly attributed to difference in mean BMI, i.e. the effect of the *FTO* minor allele tended to be larger in populations with a mean BMI ≥ 24 kg/m², compared with those with a mean BMI < 24 kg/m².

FTO-rs9939609 explained 0.16% and 0.20% of the inter-individual variation in BMI in East and South Asian populations, respectively. The proportion of variation in other obesity-related continuous traits explained by *FTO*-rs9939609 was $< 0.10\%$ (ESM Table 2).

Publication bias The funnel plots for the associations with obesity, type 2 diabetes, waist circumference, WHR and body fat percentage were symmetrical and the results for Begg’s and Egger’s tests were non-significant ($p \geq 0.10$),

indicating that our results were not affected by publication bias (ESM Fig. 7). However, there was some evidence of publication bias and/or genetic heterogeneity for BMI (Begg’s test, $p=0.08$; Egger’s test, $p=0.07$) and hip circumference (Begg’s test, $p=0.03$; Egger’s test, $p=0.08$; ESM Fig. 7).

Discussion

This meta-analysis, combining data of 96,551 Asians from 32 populations, further confirms that genetic variation in *FTO* is associated with increased risk of obesity in East and South Asians. Despite differences in genetic background and obesity susceptibility between East and South Asians, the effect of *FTO* on obesity and related traits was generally




Fig. 3 Association of *FTO*-rs9939609 (or proxy) with type 2 diabetes. Study-specific association analyses assumed an additive genetic model adjusted for age and sex. Effect sizes were combined using random-effects meta-analyses (DerSimonian–Laird method)

similar to, or only somewhat smaller than, those reported for white Europeans. We furthermore confirm that variation in *FTO* is associated with increased risk of type 2 diabetes, an association that, unlike in white Europeans, is not abolished after adjustment for BMI in both East and South Asians.

Large-scale studies in individuals of white European descent have reported that each additional *FTO* minor allele increases the odds of obesity by 1.20–1.32-fold [1, 5, 7, 47]. The association with obesity observed in Asians in the present study was remarkably similar, with each additional minor allele increasing obesity risk by 1.25-fold (95% CI 1.19, 1.31), consistent with the association observed for obesity in previous literature-based meta-analyses of case-control studies in East and South Asians [18, 29, 30].

The association of the *FTO* variant with overweight was the same in East and South Asians (OR 1.13 per minor

allele) and very similar to the effects (ORs ranging from 1.13 to 1.18) that have been reported in large-scale studies of white Europeans [1, 7, 47]. While the effect sizes observed for the influence of *FTO* on obesity and overweight in Asians are very similar to those of Europeans, it should be noted that the definitions of obesity and overweight are different, as BMI cut-offs are somewhat lower in Asians than in Europeans, consistent with the association of BMI with metabolic disease [48].

The *FTO* minor allele increases BMI by 0.26 kg/m² (equivalent to ~750 g/allele for a person 1.7 m tall) in Asians, with very similar results for East and South Asians. This observation suggests that the effect of *FTO* on BMI in Asians is substantially smaller than the effect observed in a meta-analysis of more than 125,000 white Europeans (0.39 kg/m² per minor allele, or 1,130 g per minor allele) [7]. This difference may be due to the fact that BMI in




Fig. 4 Association of *FTO*-rs9939609 (or proxy) with type 2 diabetes adjusted for BMI. Study-specific association analyses assumed an additive genetic model adjusted for age, sex, and BMI. Effect sizes were combined using random-effects meta-analyses (DerSimonian–Laird method)

Asians does not represent exactly the same adiposity phenotype as in Europeans. However, given that other large-scale studies in white Europeans have reported effects for *FTO* on BMI that range between 0.26 and 0.39 kg/m², the comparison between Asians and Europeans should be made with caution [1, 3, 5, 15, 47]. The *FTO* variant also showed convincing association with measures of fat distribution such as waist and hip circumference and WHR in Asians. Despite the often described difference in abdominal obesity between East and South Asians, the effect sizes were very similar in the two groups. Consistent with the observations for BMI, the effect sizes tended to be somewhat smaller than those reported for white Europeans. For example, each additional *FTO* minor allele increased waist circumference by 0.51 cm in Asians, whereas large-scale studies in Europeans have reported an increase of 0.73–1.00 cm [1, 9, 47].

As the MAF of the *FTO* variant is substantially lower in Asians (East Asians, ~17%; South Asians, ~32%) than in white Europeans (~45%), and as the effect of this allele on obesity-related traits is similar or somewhat lower in Asians than in white Europeans, the overall contribution of genetic variation in *FTO* to obesity susceptibility will be lower in Asians, in particular East Asians. For example, the *FTO* variant explained less of the inter-individual variation in BMI in Asians (East Asians, 0.16%; South Asians, 0.20%) than in white Europeans (0.34%) [7]. Furthermore, the low risk allele frequency led to a lower PAR for the risk of obesity (East Asians, 8.3%; South Asians, 10.6%) and overweight (East Asians, 4.1%; South Asians, 7.8%) in Asians than in white Europeans (obesity, 20.4%; overweight, 12.7%) [1].

The *FTO* locus was first identified in a GWAS for type 2 diabetes in white Europeans, i.e. each minor allele




Fig. 5 Association of *FTO*-rs9939609 (or proxy) with BMI. Study-specific association analyses assumed an additive genetic model adjusted for age and sex. Effect sizes were combined using random-effect meta-analyses (DerSimonian–Laird method)

increased the odds of diabetes by 1.15-fold [1]. However, after adjustment for BMI, the association between the *FTO* variant and type 2 diabetes was completely abolished (OR 1.03), suggesting that *FTO* is primarily an obesity-susceptibility locus [1]. In our meta-analysis, we observed a similar effect of *FTO* on risk of type 2 diabetes, with each minor allele increasing the odds by 1.15-fold. Interestingly, adjustment for BMI did not abolish the association, but only slightly attenuated it to a 1.10-fold increased risk of type 2 diabetes for each additional minor allele. These observations were similar in East and South Asians, suggesting that the *FTO* locus influences the risk of type 2 diabetes, at least in part, independently of its effect on BMI. The reason for the discrepancy between the original

observations in Europeans and our observations in Asians are not known, but may be due to the fact that *FTO* seems to have a smaller effect on BMI in Asians than in Europeans. It may also be due to the fact that BMI, as suggested above, represents a different adiposity phenotype in Asians than in Europeans because of differences in body composition. Although BMI is a marker for general adiposity, it does not distinguish between fat mass and fat-free mass and does not reflect regional fat distribution. Observational studies have suggested that, for a given amount of total body fat, East and South Asians have more abdominal fat and less muscle mass than white Europeans [49, 50]. However, while it has been generally believed that in white Europeans the association with type 2

diabetes is fully mediated by the effect of *FTO* on BMI, not all studies confirm this observation. A recent large-scale study in 41,504 Scandinavians found that the *FTO* minor allele indeed increased type 2 diabetes risk (OR 1.13), but this association remained present (OR 1.09) after adjustment for BMI, consistent with the observations in the present study. The biological pathways that underlie the independent association between *FTO* variation with obesity and type 2 diabetes remain unclear. However, results of gene expression studies have shown that *FTO* expression in human islets cells is not associated with BMI [51], whereas *FTO* mRNA and protein levels in muscle are increased in individuals with type 2 diabetes compared with non-diabetic obese individuals or healthy lean controls [52]. Furthermore, *FTO* overproduction in myotubes suggested a role for *FTO* in oxidative metabolism, lipogenesis and oxidative stress in muscle, a cluster of metabolic defects characteristic of type 2 diabetes [52].

Despite the fact that our meta-analyses included Asians with different genetic backgrounds, the overall heterogeneity of the association effects was generally only low to moderate. Interestingly, we found that the associations were generally very similar in East and South Asians, although these populations are known to have genetically different origins [53]. Furthermore, we found no differences between men and women, consistent with the observations in white Europeans [7]. We found some evidence that age may contribute to the heterogeneity of the association between *FTO* and BMI. Life course effects have been reported in white Europeans [54], and longitudinal analyses will be needed to establish this in Asian populations. Longitudinal studies are also more appropriate than cross-sectional studies for disentangling the intricate interplay between *FTO*, obesity and type 2 diabetes throughout life [15].

It should be noted that the association between *FTO* variation and obesity risk in Asians had been established in three earlier meta-analyses [18, 29, 30]. These meta-analyses were substantially smaller than the present ones and focused solely on case–control analyses of obesity and type 2 diabetes, while no continuous traits were studied. The meta-analysis by Liu et al [18] included individuals of East and South Asian origin, which were analysed together without comparison of effect sizes between the two populations. This study also examined the association with type 2 diabetes, but did not explore the association after adjustment for BMI [18]. Furthermore, the three previous meta-analyses were all literature-based and thus more prone to publication bias, whereas our meta-analysis was designed on the basis of a de novo analysis of data according to a standardised plan in all studies identified as having available data and agreement to participate. No

evidence of publication bias was observed except for the associations with BMI and hip circumference. The analytical consistency across studies helped minimise between-study heterogeneity. Although our results are representative of individuals of Southeast Asian, East Asian and South Asian descent, the association of *FTO* with risk of obesity and type 2 diabetes in other Asian populations remains to be examined.

In summary, we have firmly established that genetic variation in the first intron of *FTO* is associated with increased risk of obesity and type 2 diabetes in Asians, with effect sizes similar to those in Europeans. Furthermore, we confirm that the association of *FTO* with risk of type 2 diabetes is partly independent of BMI.

Acknowledgements A full list of acknowledgements can be found in the ESM. This work was supported by the following: Hong Kong Government Research Grants Council Central Allocation Scheme (CUHK 1/04C), Research Grants Council Earmarked Research Grant (CUHK4724/07M) and the Innovation and Technology Fund of the Government of the Hong Kong SAR (ITS/487/09FP); National Institutes of Health (DK078150, TW05596, HL085144, TW008288) and pilot funds (RR20649, ES10126, and DK56350); National Institutes of Health (R01 AR050496, R21 AG027110, R01 AG026564, R01 AR057049-01A1, R21 AA015973) and Specialized Center of Research (P50 AR055081) and National Science Foundation of China (81000363, 31000554) and the PhD Programs Foundation of Ministry of Education of China (20100201120058) and the Fundamental Research Funds for the Central Universities, Shanghai Leading Academic Discipline Project (S30501); National Research Foundation of Korea (NRF, no. 20100020617); the Japanese Society for the Promotion of Science (17209021) and of Priority Area ‘Applied Genomics’ (1601223, 17019028, 18018020, 20018026); the Korea Health 21 R&D Project, Korean Ministry of Health & Welfare (00-PJ3-PG6-GN07-001); the National Institute for Health Research Comprehensive Biomedical Research Centre at Imperial College Healthcare NHS Trust, the British Heart Foundation (SP/04/002), the Medical Research Council (G0700931), the Wellcome Trust (084723/Z/08/Z) and the National Institute for Health Research (RP-PG-0407-10371); the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2009KIP401), the Chief Scientist Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (SIBS2008006), the Knowledge Innovation Program Project of the Chinese Academy of Sciences (KSCX1-YW-02), the National Natural Science Foundation of China (30930081), and National High Technology Research and Development Program (863 Program) (2009AA022704), National 973 Program (2011CB504002); the National Science Council (NSC 95-3112-B002-002, NSC 96-2752-B002-008-PAE) of Taiwan; major program of Shanghai Municipality for Basic Research (08dj1400601), National Natural Science Foundation of China (30800617); National Institute of Health (NIH/FIC KO1 TW006087, NIH/NIDDK R01 DK082766); the Program for the National Natural Science Foundation of China (NSFC-30872116) and New Century Excellent Talents in the University of China (NCET-04-0707); Council of Scientific and Industrial Research, Government of India (NWP0032); the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services (N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221) and the National Institute of Diabetes and Digestive and Kidney Diseases R01 (DK062290) from the National Institutes of Health.

Contribution statement RJFL, HL and XL contributed to the conception and design of the study. CL and TOK performed the literature search, designed the analysis plan, performed the meta-analyses and researched the data. HL, TOK, CL and RJFL wrote the manuscript. HL, JZ, YL, CH, ZY, WZ, WB, SC, YW, TY, AS, BYC, CSY, DZ, FT, KY, JCC, KRM, LFB, MI, EN, NL, TF, SK, WW, CVJ, WL, YC, YX, YG, SL, YS, SHK, HDS, KSP, CHDF, JYK, PCS, KSL, WZ, XS, HD, HI, GVK, DKS, LC, LL, RH, YK, MD, KH, WJ, JSK, JCC, GRC, RCM, SM, RD, MY, RT, NK, XL and RJFL collected study-specific data, analysed the study-specific data according to the standardised analysis plan, and reviewed and edited the manuscript. All authors have approved the final version of the manuscript to be published.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Frayling TM, Timpson NJ, Weedon MN et al (2007) A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 316:889–894
2. Scuteri A, Sanna S, Chen WM et al (2007) Genome-wide association scan shows genetic variants in the *FTO* gene are associated with obesity-related traits. *PLoS Genet* 3:e115
3. Loos RJ, Lindgren CM, Li S et al (2008) Common variants near *MC4R* are associated with fat mass, weight and risk of obesity. *Nat Genet* 40:768–775
4. Willer CJ, Speliotes EK, Loos RJ et al (2009) Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat Genet* 41:25–34
5. Thorleifsson G, Walters GB, Gudbjartsson DF et al (2009) Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet* 41:18–24
6. Chambers JC, Elliott P, Zabaneh D et al (2008) Common genetic variation near *MC4R* is associated with waist circumference and insulin resistance. *Nat Genet* 40:716–718
7. Speliotes EK, Willer CJ, Berndt SI et al (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet* 42:937–948
8. Lindgren CM, Heid IM, Randall JC et al (2009) Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. *PLoS Genet* 5:e1000508
9. Heard-Costa NL, Zillikens MC, Monda KL et al (2009) *NRXN3* is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. *PLoS Genet* 5:e1000539
10. Heid IM, Jackson AU, Randall JC et al (2010) Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat Genet* 42:949–960
11. Meyre D, Delplanque J, Chevre JC et al (2009) Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat Genet* 41:157–159
12. Scherag A, Dina C, Hinney A et al (2010) Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and German study groups. *PLoS Genet* 6:e1000916
13. Kring SI, Holst C, Zimmermann E et al (2008) *FTO* gene associated fatness in relation to body fat distribution and metabolic traits throughout a broad range of fatness. *PLoS One* 3:e2958
14. Hotta K, Nakamura M, Nakamura T et al (2010) Polymorphisms in *NRXN3*, *TFAP2B*, *MSRA*, *LYPLAL1*, *FTO* and *MC4R* and their effect on visceral fat area in the Japanese population. *J Hum Genet* 55:738–742
15. Hertel JK, Johansson S, Sonestedt E et al (2011) *FTO*, Type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. *Diabetes* 60:1637–1644
16. Li H, Wu Y, Loos RJ et al (2008) Variants in the fat mass- and obesity-associated (*FTO*) gene are not associated with obesity in a Chinese Han population. *Diabetes* 57:264–268
17. Horikoshi M, Hara K, Ito C et al (2007) Variations in the *HHEX* gene are associated with increased risk of type 2 diabetes in the Japanese population. *Diabetologia* 50:2461–2466
18. Liu Y, Liu Z, Song Y et al (2010) Meta-analysis added power to identify variants in *FTO* associated with type 2 diabetes and obesity in the Asian population. *Obesity (Silver Spring)* 18:1619–1624
19. Karasawa S, Daimon M, Sasaki S et al (2010) Association of the common fat mass and obesity associated (*FTO*) gene polymorphism with obesity in a Japanese population. *Endocr J* 57:293–301
20. Hotta K, Nakata Y, Matsuo T et al (2008) Variations in the *FTO* gene are associated with severe obesity in the Japanese. *J Hum Genet* 53:546–553
21. Ng MC, Tam CH, So WY et al (2010) Implication of genetic variants near *NEGR1*, *SEC16B*, *TMEM18*, *ETV5/DGKG*, *GNPDA2*, *LIN7C/BDNF*, *MTCH2*, *BCDIN3D/FAIM2*, *SH2B1*, *FTO*, *MC4R*, and *KCTD15* with obesity and type 2 diabetes in 7705 Chinese. *J Clin Endocrinol Metab* 95:2418–2425
22. Tan JT, Dorajoo R, Seielstad M et al (2008) *FTO* variants are associated with obesity in the Chinese and Malay populations in Singapore. *Diabetes* 57:2851–2857
23. Chang YC, Liu PH, Lee WJ et al (2008) Common variation in the fat mass and obesity-associated (*FTO*) gene confers risk of obesity and modulates BMI in the Chinese population. *Diabetes* 57:2245–2252
24. Cheung CY, Tso AW, Cheung BM et al (2010) Obesity susceptibility genetic variants identified from recent genome-wide association studies: implications in a Chinese population. *J Clin Endocrinol Metab* 95:1395–1403
25. Cha SW, Choi SM, Kim KS et al (2008) Replication of genetic effects of *FTO* polymorphisms on BMI in a Korean population. *Obesity (Silver Spring)* 16:2187–2189
26. Lee HJ, Kim IK, Kang JH et al (2010) Effects of common *FTO* gene variants associated with BMI on dietary intake and physical activity in Koreans. *Clin Chim Acta* 411:1716–1722
27. Marvelle AF, Lange LA, Qin L, Adair LS, Mohlke KL (2008) Association of *FTO* with obesity-related traits in the Cebu Longitudinal Health and Nutrition Survey (CLHNS) Cohort. *Diabetes* 57:1987–1991
28. Cho YS, Go MJ, Kim YJ et al (2009) A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat Genet* 41:527–534
29. Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M (2011) *FTO* gene polymorphisms and obesity risk: a meta-analysis. *BMC Med* 9:71
30. Xi B, Mi J (2009) *FTO* polymorphisms are associated with obesity but not with diabetes in East Asian populations: a meta-analysis. *Biomed Environ Sci* 22:449–457

31. Dorajoo R, Blakemore AI, Sim X et al (2011) Replication of 13 obesity loci among Singaporean Chinese. Malay and Asian-Indian populations. *Int J Obes (Lond)*. doi:10.1038/ijo.2011.86
32. Ramya K, Radha V, Ghosh S, Majumder PP, Mohan V (2010) Genetic variations in the *FTO* gene are associated with type 2 diabetes and obesity in south Indians (CURES-79). *Diabetes Technol Ther* 13:33–42
33. Yajnik CS, Janipalli CS, Bhaskar S et al (2009) *FTO* gene variants are strongly associated with type 2 diabetes in South Asian Indians. *Diabetologia* 52:247–252
34. Ng MC, Park KS, Oh B et al (2008) Implication of genetic variants near *TCF7L2*, *SLC30A8*, *HHEX*, *CDKAL1*, *CDKN2A/B*, *IGF2BP2*, and *FTO* in type 2 diabetes and obesity in 6,719 Asians. *Diabetes* 57:2226–2233
35. Li X, Song F, Jiang H et al (2010) A genetic variation in the fat mass- and obesity-associated gene is associated with obesity and newly diagnosed type 2 diabetes in a Chinese population. *Diabetes Metab Res Rev* 26:128–132
36. Shi J, Long J, Gao YT et al (2010) Evaluation of genetic susceptibility loci for obesity in Chinese women. *Am J Epidemiol* 172:244–254
37. Omori S, Tanaka Y, Takahashi A et al (2008) Association of *CDKAL1*, *IGF2BP2*, *CDKN2A/B*, *HHEX*, *SLC30A8*, and *KCNJ11* with susceptibility to type 2 diabetes in a Japanese population. *Diabetes* 57:791–795
38. Tabara Y, Osawa H, Guo H et al (2009) Prognostic significance of *FTO* genotype in the development of obesity in Japanese: the J-SHIP study. *Int J Obes (Lond)* 33:1243–1248
39. Han X, Luo Y, Ren Q et al (2010) Implication of genetic variants near *SLC30A8*, *HHEX*, *CDKAL1*, *CDKN2A/B*, *IGF2BP2*, *FTO*, *TCF2*, *KCNQ1*, and *WFS1* in type 2 diabetes in a Chinese population. *BMC Med Genet* 11:81
40. Sanghera DK, Ortega L, Han S et al (2008) Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: *PPARG2* (Pro12Ala), *IGF2BP2*, *TCF7L2* and *FTO* variants confer a significant risk. *BMC Med Genet* 9:59
41. Takeuchi F, Yamamoto K, Katsuya T et al (2011) Association of genetic variants for susceptibility to obesity with type 2 diabetes in Japanese individuals. *Diabetologia* 54:1350–1359
42. Shu XO, Long J, Cai Q et al (2010) Identification of new genetic risk variants for type 2 diabetes. *PLoS Genet* 6: e1001127
43. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in China (2002) Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci* 15:83–96
44. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* 7:177–188
45. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. *Stat Med* 21:1539–1558
46. Ng MC, Tam CH, Lam VK, So WY, Ma RC, Chan JC (2007) Replication and identification of novel variants at *TCF7L2* associated with type 2 diabetes in Hong Kong Chinese. *J Clin Endocrinol Metab* 92:3733–3737
47. Li S, Zhao JH, Luan J et al (2009) Cumulative effects and predictive value of common obesity-susceptibility variants identified by genome-wide association studies. *Am J Clin Nutr* 91:184–190
48. Consultation WHOE (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 363:157–163
49. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL (2007) Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). *Am J Clin Nutr* 86:353–359
50. Chan JC, Malik V, Jia W et al (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 301:2129–2140
51. Kirkpatrick CL, Marchetti P, Purrello F et al (2010) Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. *PLoS One* 5:e11053
52. Bravard A, Lefai E, Meugnier E et al (2011) *FTO* is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. *Diabetes* 60:258–268
53. Consortium HP-AS, Abdulla MA, Ahmed I et al (2009) Mapping human genetic diversity in Asia. *Science* 326:1541–1545
54. Hardy R, Wills AK, Wong A et al (2009) Life course variations in the associations between *FTO* and *MC4R* gene variants and body size. *Hum Mol Genet* 19:545–552
55. Sha BY, Yang TL, Zhao LJ et al (2009) Genome-wide association study suggested copy number variation may be associated with body mass index in the Chinese population. *J Hum Genet* 54:199–202
56. Hu C, Zhang R, Wang C et al (2009) *PPARG*, *KCNJ11*, *CDKAL1*, *CDKN2A-CDKN2B*, *IDE-KIF11-HHEX*, *IGF2BP2* and *SLC30A8* are associated with type 2 diabetes in a Chinese population. *PLoS One* 4:e7643
57. Wen J, Ronn T, Olsson A et al (2010) Investigation of type 2 diabetes risk alleles support *CDKN2A/B*, *CDKAL1*, and *TCF7L2* as susceptibility genes in a Han Chinese cohort. *PLoS One* 5:e9153
58. Cha S, Koo I, Park BL et al (2009) Genetic effects of *FTO* and *MC4R* polymorphisms on body mass in constitutional types. *Evid Based Complement Alternat Med*. doi:10.1093/ecam/nep162
59. Takeuchi F, Serizawa M, Yamamoto K et al (2009) Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. *Diabetes* 58:1690–1699

